全球抗生素市场研究报告 2010 版 Antibiotics - A Global Strategic Business Report

Transcription

1 /wepdwukltuyot 全球抗生素市场研究报告 2010 版 Antibiotics - A Global Strategic Business Report 联系购买电话 : 公司名称 : 佐思信息公司地址 : 北京市海淀区苏州街 18 号院长远天地大厦 A2 座 室 (100080) Countries covered: Global This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through A seven-year historic analysis is also provided for these markets. The report profiles 197 companies including many key and niche players such as Abbott Laboratories, Astellas Pharma, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., and Toyama Chemical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report. Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study Penicillin Cephalosporins Macrolides Quinolones Carbapenems Other Antibiotics Aminoglycosides Tetracyclines Sulfonamides Mupirocin

2 Glycopeptides Synercid Oxazolidinones Linezolid 2. INDUSTRY OVERVIEW Antibiotic Resistance and Generic Competition to Impact Long Term Growth New Regulations Guiding Usage of Drugs to Drive Growth Current & Future Analysis 3. MARKET DYNAMICS Anti-Bacterials Segment Drives Global Anti- Infectives Market Antibiotic Resistance - A Primary Growth Inhibitor Antibiotic-Resistant Bacteria by Type Patent Expiries Commoditize Antibiotics Patent Expiries of Leading Drugs in the Recent Past, Current, and Future ( ) Anti-MRSA Antibiotics Find Their Way Table 1: World MRSA Treatments (2007 & 2008) : Percentage Share Breakdown by Leading Antibiotic Drugs -Vancomycin, Zyvox, Cubicin and Tygacil (includes corresponding Key Antibiotics in Pipeline 4. COMPETITION Highly Competitive Market Table 2: Leading Players in the Worldwide Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Glaxo Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others GlaxoSmithKline - The Undisputed Leader of Penicillin Market Table 3: Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes corresponding GlaxoSmithKline Leads Cephalosporin Market Table 4: Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others Pfizer Dominates Macrolides Market Table 5: Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic Table 6: Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others Merck Rules Carbapenems Market Table 7: Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding 5. PRODUCT OVERVIEW Antibiotics - An Introduction Antibiotic Resistance b-lactams Classification of Antibiotics Key Milestones in Antibiotic Development Antibiotic Types Penicillin History About the Drug Cephalosporins Treatment Effects of the Drug Macrolides

3 Treatment Quinolones Table 8: Leading Global Ciprofloxacin Brands: ( ) (includes corresponding Carbapenems Other Antibiotics Aminoglycosides Treatment Effects of the Drug Tetracyclines Treatment Effects of the Drug Sulfonamides Treatment Effects of the Drug Mupirocin Glycopeptides Synercid Oxazolidinones Linezolid 6. RESEARCH FINDINGS New Design for Monitoring Toxin Delivery Activity of Pathogenic Bacteria Cephalosporins Effective when Compared to Penicillin FDA Bans Baytril Antibiotic for Chickens Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug Resistance Polyphor Discovers POL New Antibiotic Against Gram-Negative Bacteria 7. FDA APPROVALS/PATENTS MiddleBrook Obtains NDA Approval for MOXATAG J&JPRD Seeks FDA Approval for Doripenem Antibiotic J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole GSK Receives Approval for ALTARGO in Europe APL Receives FDA Approval for Cefpodoxime Proxetil Cubist Receives Approval to Market CUBICIN in Canada Cubist Obtains Approval to Market CUBICIN for Added Indications in EU Cubist Gains Approval for CUBICIN in Taiwan and South Korea Cethromycin Achieves FDA s Orphan Drug Designation FDA Approves Wockhardt s Cefotaxime Injection FDA Approves Doxycycline Tablets FDA Approves Clarithromycin FDA Approves Doxycycline Tablets For The US Market Johnson & Johnson Applies Doripenem For FDA Approval FDA Certifies Antibioticos do Brasil s Plant FDA Certifies ANDA For Cefdinir Capsules US FDA Approves Teva s Cefprozil Tablets FDA Certifies ANDA for Cephalexin Capsules American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection, USP Advancis s Keflex Receives FDA Approval Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US Wyeth s Mylotarq Receives Government s Approval FDA Approves Generic Version of Zithromax Pfizer Wins FDA Approval for Zmax Venus Remedies Files Second PCT for New Cephalosporins Falcon Gains US FDA Approval for its Generic Anti-Infective Solution Cadilla Receives FDA Approval to Market Clindamycin 8. RECENT INDUSTRY ACTIVITY DSM Opens Eco-friendly Antibiotics Plant ZOR-f, in the Netherlands Daiichi Leverages Ranbaxy s Network to Market Tavanic in South Africa and Romania

4 Pfizer Acquires Wyeth Durata Therapeutics Acquires Pfizer s Vicuron Pharmaceuticals Cubist Completes Acquisition of Calixa Therapeutics AstraZeneca to Acquire Novexel Tianyin and Sichuan Mingxin to Establish an Antibiotic Joint Venture Pfizer and Aurobindo Pharma Ink Agreement for Producing Off Patent Drugs BMP Sunstone to Acquire Majority Stake in Zhangjiakou Shengda Novartis to Take Over Protez Pharmaceuticals 3i to Buy Alpharma Unit NCPC to Acquire Stake in DSM s Antibiotics Division ULL Establishes New Antibiotics Unit in Himachal Pradesh Biocat to Expand Presence in the Indian Market PRWT Acquires Cherokee Chemical Unit from Merck CSPC Joins Hands with Indonesian Firms 9. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST - A PERSPECTIVE BUILDER Nisshin-Kyorin to Merge with Kyorin Pharmaceutical Schering-Plough Acquires Organon BioSciences GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals Iroko Bags Canadian Rights to Vancocin Cubist Licenses CUBICIN Rights to Merck Sagent Partners with Astral to Develop Injectable Antibiotics MR Healthcare to Manufacture New Antibiotics & Medicines Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo C&O Pharmaceutical to Distribute Meiact in China Bioton Signs Deal to Market Antibiotics in Russia Toyama Gains Marketing Approval for Geninax in Japan Forest Laboratories Acquires Cerexa Oscient Modifies Licensing Agreement With LG Life Sciences Orchid Sign Licensing & Distribution Pact With Actavis Forest Laboratories Revokes Partnership With Replidyne SRI and Blanca Collaborate To Develop & Test Carbacephem AstraZeneca To Expand Research Center For Antibiotics Jade Pharmaceutical Begins Levofloxacin s Production in China Reyoung To Start Antibiotic Production At New Facility Toyama Begins T-705 Clinical Trials SmPC For Sanofi-Aventis Ketek Updated Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic Tablets in France Antibiotice Plans To Infuse Funds For Antibiotics Production UAE Approves Pfizer s Zithromax SD 10. PRODUCT INNOVATIONS/INTRODUCTIONS Janssen-Cilag Launches Doribax - New Carbapenem Antibiotic MIT Scientists Develop a New Antibiotic, Rhodostreptomycin Watson Pharma Introduces Biaxin XL s Generic Version 11. PRODUCT INNOVATIONS IN THE RECENT PAST - A PERSPECTIVE BUILDER Toyama Launches New Garenoxacin Quinolone Antibiotic Wockhardt to Introduce Cefprozil in the US MSD India Launches Invanza in India Orchid Chemicals to Introduce Three New Drugs in the US DUSA Pharmaceuticals Releases ClindaReach Mylan Releases Cipro s Generic Version Macrolide Antibiotic Developed In the US University of Michigan Devises NMR Spectroscopy For Antibiotics Glycopeptide-Cephalosporin Antibiotics Developed In The US Neosil Tests NEO 101 Antibiotic New Antibiotic Developed By Canadian Inventors Abbott Canada Releases FACTIVE Antibiotic Tablets In Canada Penicillin Binding Protein Found In Japan

5 Venus Remedies Releases Mucomelt-Forte 12. FOCUS ON SELECT GLOBAL PLAYERS Abbott Laboratories (USA) Astellas Pharma, Inc. (Japan) Bayer HealthCare AG (Germany) Bristol-Myers Squibb Co. (USA) Cubist Pharmaceuticals, Inc. (USA) Daiichi Sankyo Company, Limited (Japan) Eli Lilly and Co. (USA) GlaxoSmithKline Plc (UK) Johnson & Johnson (USA) Kyorin Pharmaceutical Co., Ltd. (Japan) LG Life Sciences Limited (Korea) MiddleBrook Pharmaceuticals, Inc. (USA) Novartis AG (Switzerland) Pfizer Inc. (USA) Pliva d.d. (Croatia) Roche (Switzerland) Sanofi-Aventis SA (France) Takeda Pharmaceutical Company, Ltd. (Japan) Toyama Chemical Co., Ltd. (Japan) 13. GLOBAL MARKET PERSPECTIVE Table 9: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Table 10: World Historic Review for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed Table 11: World 11-Year Perspective for Antibiotics by Geographic Region - Percentage and Rest of World Markets for Years 2005, 2010 & 2015 Table 12: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Table 13: World Historic Review for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed Table 14: World 11-Year Perspective for Penicillin by Geographic Region - Percentage and Rest of World Markets for Years 2005, 2010 & 2015 Table 15: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Table 16: World Historic Review for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Table 17: World 11-Year Perspective for Cephalosporin by Geographic Region - Percentage and Rest of World Markets for Years 2005, 2010 & 2015 Table 18: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets

6 Table 19: World Historic Review for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed Table 20: World 11-Year Perspective for Macrolides by Geographic Region - Percentage and Rest of World Markets for Years 2005, 2010 & 2015 Table 21: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Table 22: World Historic Review for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed Table 23: World 11-Year Perspective for Quinolones by Geographic Region - Percentage and Rest of World Markets for Years 2005, 2010 & 2015 Table 24: World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Table 25: World Historic Review for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed Table 26: World 11-Year Perspective for Carbapenems by Geographic Region - Percentage and Rest of World Markets for Years 2005, 2010 & 2015 Table 27: World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Table 28: World Historic Review for Other Antibiotics by Geographic Region - US, Canada, Jap an, Europe, Asia- Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Table 29: World 11-Year Perspective for Other Antibiotics by Geographic Region - Percentage and Rest of World Markets for Years 2005, 2010 & THE UNITED STATES Antibiotics Approved Between 2000 and in the United States Competition Table 30: Leading Players in the US Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Key Players Table 31: US Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Table 32: US Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed

7 Table 33: US 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & CANADA Current And Future Analysis Table 34: Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Table 35: Canadian Historic Review for Antibiotics by Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Table 36: Canadian 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & JAPAN Key Players Table 37: Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Table 38: Japanese Historic Review for Antibiotics by Product Segment - Penicillin, Table 39: Japanese 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding 17. EUROPE Table 40: European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Table 41: European Historic Review for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 Table 42: European Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Table 43: European Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets

8 Table 44: European 11-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2005, 2010 & 2015 Table 45: European 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding 17a. FRANCE Trends Over Consumption of Antibiotics - Cause of Concern Sanofi-Aventis SA - A Key Player Table 46: French Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Table 47: French Historic Review for Antibiotics by Product Segment - Penicillin, Table 48: French 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2005, 2010 & 2015 (includes corresponding 17b. GERMANY Bayer HealthCare AG - A Key Player Table 49: German Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Table 50: German Historic Review for Antibiotics by Product Segment - Penicillin, Table 51: German 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & c. ITALY Table 52: Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Table 53: Italian Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed Table 54: Italian 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & d. THE UNITED KINGDOM

9 Current And Future Analysis GlaxoSmithKline Plc - A Key Player Table 55: UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Table 56: UK Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, acrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed Table 57: UK 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2005, 2010 & e. SPAIN Market Analysis Table 58: Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Table 59: Spanish Historic Review for Antibiotics by Product Segment - Penicillin, Table 60: Spanish 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding 17f. REST OF EUROPE Poland Table 61: Polish Market for Antibiotics (2008): Percentage Breakdown of Market Share by Leading Companies - GSK Pharma, Bioton, Sandoz Corp, Ranbaxy and Others (includes corresponding Focus On Select Players Table 62: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 Table 63: Rest of Europe Historic Review for Antibiotics by Product Segment - Penicillin, Table 64: Rest of Europe 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & ASIA-PACIFIC India Rising Prices of Penicillin G to Affect Antibiotics Production Market for Injectable Antibiotics Poised to Grow Cipla, Pharmaceutical Market Leader in 2009 China Carbapenem Witnesses Robust Growth in China

10 Key Players Ranbaxy Laboratories Ltd. (India) Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 Table 66: Asia-Pacific Historic Review for Antibiotics by Product Segment - Penicillin, Table 67: Asia-Pacific 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding 19. REST OF WORLD Table 68: Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Ye ars 2007 through 2015 Table 69: Rest of World Historic Review for Antibiotics by Product Segment - Penicillin, Table 70: Rest of World 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 COMPETITION Total Companies Profiled: 197 (including Divisions/Subsidiaries - 238) Region/Country Players The United States 48 Canada 8 Japan 11 Europe France Germany The United Kingdom Italy Spain Rest of Europe 29 Asia-Pacific (Excluding Japan) 87 Middle East 11 Latin America 4 Africa 1